Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

Endpoint:
short-term repeated dose toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
Sep 1973 - Nov 1973
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Acceptable, well-documented report which meets basic scientific principles.

Data source

Referenceopen allclose all

Reference Type:
study report
Title:
Unnamed
Year:
1977
Report date:
1977
Reference Type:
publication
Title:
OECD SIDS Dimethylformamide, Final April 2004
Author:
OECD
Year:
2004
Bibliographic source:
OECD SIDS Dimethylformamide

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
Deviations:
not specified
Principles of method if other than guideline:
no original report (source: present already existing item)
GLP compliance:
no

Test material

Constituent 1
Reference substance name:
Dimethylformamide
IUPAC Name:
Dimethylformamide
Details on test material:
- Name of test material (as cited in study report): N,N-dimethylformamide

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: WIGA, sulzfeld, Germany
- Age at study initiation: 32 days
- Weight at study initiation: male: 104-120 g; female: 104 - 122 g
- Housing: 3 per cage
- Diet: Altromin-R, Altrogge, Germany ad libitum
- Water: tap water ad libitum
- Acclimation period: 13 days


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±2 °C
- Humidity (%): 55±5 %
- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
water
Analytical verification of doses or concentrations:
not specified
Duration of treatment / exposure:
28 days
Frequency of treatment:
5 d/w
Doses / concentrations
Remarks:
Doses / Concentrations:
250, 500, 1000 and 2000 µl/kg (~238, 475, 950, 1900 mg/kg)
Basis:
nominal in water
No. of animals per sex per dose:
10
Control animals:
other: aqua bidest

Examinations

Observations and examinations performed and frequency:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: twice weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes

HAEMATOLOGY: Yes
- Time schedule for collection of blood: 10 days before the start of the study and direclty before the last substance administration.
- How many animals: all
- Parameters examined: mean cell haemoglobin concentration, haemoglobin, erythrocytes, haematocrit, thrombocytes, lycocytes, differential count, mean cell volume, mean cell haemoglobin

CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: 10 days before the start of the study and direclty before the last substance administration.
- How many animals: all
- Parameters examined: urea, chloride, creatinine, calcium, glucose total, bilirubin, albumin, phosphorus (as phosphate), total protein, lipids, sodium, potassium, carbon dioxide, alkaline phosphatase activity, glutamate-pyruvat transfaminase activity,

URINALYSIS: Yes
- Time schedule for collection of urine: day 21 or 22
- Parameters examined: pH, protein, glucose, bilirubin, sediment

Sacrifice and pathology:
GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes; heart, lung, thyroid, stomach, duodenum, jejunum, ileum, mesenteric lymphnodes, liver, pancreas, spleen, kidneys, adrenals, urinary bladder, testes and ovaries and brain.
Other examinations:
Body weight and organ weights of heart, liver, kidneys, spleen, thyroid, adrenals, testes, uterus and ovary were determined.
Statistics:
Statistical calculations (t-Test; x2-Test) were done for clinical, pathological and clinical chemistry data as well as for data from hematology and urinalysis.

Results and discussion

Results of examinations

Details on results:
CLINICAL SIGNS AND MORTALITY
At the highest dose group all animals died, mostly during the first 5 days of substance application. The animals in the highest dose group showed piloerection, apathy, anemia, dyspnoea, hyperthermia, lateral position.
At 950 mg DMF/kg the general state of health was reduced (in male animals already beginning in study week 1, in female animals at the end of study week 3). 4 male animals (on study days 7, 8, 14 and 19) and one female animal (after 15 substance applications) died.

BODY WEIGHT AND WEIGHT GAIN
The animals in the highest dose group showed reduced body weight gain already after the first treatment. At 950 mg DMF/kg significantly reduced body weight when compared to the controls (at the end of the study for male animals 28% lower, and for female animals 21 % lower than control). At 475 mg/kg significantly reduced body weight when compared to the control animals (14.6% lower than controls) were seen.

FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
The animals in the highest dose group showed reduced reduced food consumption already after the first treatment. At 950 mg DMF/kg the animals showed a significantly reduced food consumption (up to 36% reduced in the males and up to 40% reduced in the females). At 238 and 475 mg/kg reduced food consumption in the male animals were seen.

HAEMATOLOGY
950 mg/kg: 1 male and 2 females showed an extreme decrease in thrombocytes and the males an increase in segmented granuloctes and decrease in lymphocytes.

CLINICAL CHEMISTRY
At 950 mg DMF/kg hepatic damage was represented by changes in clinical chemistry values (increased total bilirubin, increased enzyme values, i.e. GPT, AP) and disturbances in kidney function were represented by elevated urea (in 2 of 9 female animals) and creatinine values (in all animals of the 950 mg/kg dose group).

URINALYSIS
No abnormalities

ORGAN WEIGHTS
Relative liver weights were increased in both sexes and relative kidney weights were increased in the male animals at 950 mg/kg. At 238 and 475 mg/kg in both sexes increased relative liver weights and in the males increased relative kidney weights were observed, however without histopathological correlates.

HISTOPATHOLOGY: NON-NEOPLASTIC
Histologically an acute to subacute hemorrhagic liver dystrophy with necrosis was found in the animals of 950 mg/kg and the highest dose group.



Effect levels

open allclose all
Dose descriptor:
NOAEL
Effect level:
238 mg/kg bw/day (nominal)
Sex:
male/female
Basis for effect level:
other: overall effects
Dose descriptor:
LOAEL
Effect level:
475 mg/kg bw/day (nominal)
Sex:
male/female
Basis for effect level:
other: body weight

Target system / organ toxicity

Critical effects observed:
not specified

Any other information on results incl. tables

The repeated application of dimethylformamide in doses from 950 mg/kg onwards leads to distinct acute hemorrhagic liver dystrophy with necrosis. Females were in general more tolerant to dimethylformamide.

Applicant's summary and conclusion

Executive summary:

In the present study, Sprague-Dawley rats received 250, 500, 1000 and 2000 µl N,N-dimethylformamide /kg bw (about 238, 475, 950 and 1900 mg/kg bw/day) by gavage on 5 days/week. In the highest dose group all animals died, mostly at the beginning of the study. At 100 µl/kg bw/day all animals affected by reduced food consumption and reduced body weight, males already at the beginning, females at the end of the study. Hepatic injury was characterized by changes in clinical chemistry values, e.g. increased enzyme activities. Relative liver weights were increased in both sexes. Histological examination revealed an acute to subacute hemorrhagic liver dystrophy with necrosis in both sexes in the two high dose groups. Disturbances in kidney function were characterized by elevated urea (females) and creatinine values, the latter one in both sexes. Relative kidney weights were increased in the males. At 250 and 500 μl/kg bw/day reduced food consumption in the males and at 500 μl/kg bw/day reduced body weight was observed in the males. For the observation of increased relative liver weights in both sexes and of increased relative kidney weights in the males no histopathological correlate was found.